Key Highlights

  • 0.11 is the negative consensus EPS estimate per the screener snapshot for Biofrontera Inc. (NASDAQ:BFRI), which is due to report third quarter 2026 results before the market opens on November 13, 2026.
  • 12.0 million is the USD net product Revenue for the second quarter of 2026, up 32.9% from USD 9.0 million, with gross Margin rising to 80% from 71% a year earlier.
  • 0.6 million is the USD net loss for the second quarter, or USD 0.05 per share, versus USD 5.3 million, or USD 0.57 per share, while adjusted EBITDA improved to negative USD 0.2 million.
  • 13.92 million is the USD market Capitalization per the screener snapshot, a nano-cap level, while cash was USD 4.7 million at June 30, 2026 and an FDA decision date of September 28, 2026 was set.

What Investors Expect From Biofrontera Inc. (NASDAQ:BFRI) on November 13, 2026

Biofrontera Inc. is listed to report third quarter 2026 results before the market opens (BMO) on November 13, 2026. The consensus estimate per the screener snapshot is a loss of USD 0.11 per share, wider than the second quarter loss of USD 0.05 per share. The six-month loss was USD 0.44 per share versus USD 1.05. Market capitalization per the screener snapshot is USD 13.92 million, a nano-cap level carrying high Volatility and liquidity risk. Published coverage showed the stock at USD 1.28 with a 52-week range of USD 0.55 to USD 1.40.

The Rationale: Last Reported Quarter and Management Outlook for Biofrontera Inc. (NASDAQ:BFRI)

In the second quarter of 2026, selling, general and administrative expense fell to USD 9.7 million from USD 10.6 million on lower litigation fees, and Research and Development expense fell to USD 0.4 million from USD 0.9 million. First half net product revenue was USD 22.1 million, up 25.4% from USD 17.6 million, with a net loss of USD 5.4 million versus USD 9.5 million. Operating cash use dropped to USD 1.7 million from USD 7.2 million. No numeric guidance was found; management said the company is closer to breakeven in 2026 after the October 2025 transaction with Biofrontera AG improved Ameluz costs.

Valuation, Liquidity and Risks for Biofrontera Inc. (NASDAQ:BFRI)

Per the screener snapshot, the Market Value is USD 13.92 million. Cash was USD 4.7 million at June 30, 2026, total liabilities were USD 18.1 million and stockholders' Equity was USD 6.0 million, down from USD 10.5 million at year-end. Debt and share count were not found in published coverage. The superficial basal cell carcinoma PDUFA date was September 28, 2026, and the outcome was not found. Revenue growth was aided by price increases and some orders pulled forward. Risks include thin cash, regulatory outcomes and nano-cap liquidity.

Where Things Stand

Where things stand: Biofrontera Inc. (NASDAQ:BFRI) reports third quarter 2026 results before the market opens on November 13, 2026, with a consensus EPS estimate of -0.11 and a market value of USD 13.92 million per the screener snapshot. The second quarter delivered revenue of USD 12.0 million, an 80% gross margin and adjusted EBITDA of negative USD 0.2 million, versus negative USD 5.1 million a year earlier. First half adjusted EBITDA was negative USD 3.7 million versus negative USD 9.5 million. Investors will watch whether pulled-forward orders slow growth, how cash of USD 4.7 million is used, and any update after the September 28, 2026 FDA decision date. This article is informational and is not Investment advice.